TC BioPharm to Participate in Major Investment Conference
TC BioPharm (Holdings) PLC, an innovative clinical-stage biotechnology company, is gearing up to present its advancements in gamma-delta T cell therapies at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. This significant event will take place from September 9 to 11, providing the company an opportunity to showcase its cutting-edge cancer treatment approaches.
Conference Details
The conference is set to be hosted at the esteemed Lotte New York Palace Hotel, featuring over 550 presentations. Participants will have the chance to access these presentations both live and on-demand, gaining valuable insights into various companies in the biotechnology field.
Management Presentation
At the conference, CEO Bryan Kobel will deliver a presentation outlining TC BioPharm's vision and recent progress. His talk is anticipated to emphasize the company's groundbreaking research in allogeneic gamma-delta T cell therapies, which have demonstrated encouraging results in treating conditions such as acute myeloid leukemia.
Contacting TC BioPharm
Investors and stakeholders interested in engaging with the management team are encouraged to reach out directly via email at ir@tcbiopharm.com. This channel is designed to foster discussions about the company's innovative initiatives and potential investment opportunities.
Understanding Gamma-Delta T Cell Therapies
Gamma-delta T cells are at the forefront of cancer therapy, recognized for their unique ability to differentiate between healthy and diseased tissues. This capability stems from their dual origins in both the innate and adaptive immune systems. TC BioPharm is a leader in leveraging these cells for therapeutic purposes, supported by research that validates the effectiveness of its products in clinical trials.
About TC BioPharm (Holdings) PLC
TC BioPharm is engaged in the advanced field of biopharmaceuticals, focusing on the exploration and commercialization of gamma-delta T cell therapies. With a particular emphasis on acute myeloid leukemia—where clinical data indicates human efficacy—the company is a pioneer in this specialized area of cancer treatment. Its proprietary technology, CryoTC, enables the distribution of frozen therapy products, making them ready for clinical application worldwide.
Frequently Asked Questions
What is TC BioPharm's core area of focus?
TC BioPharm specializes in developing gamma-delta T cell therapies for cancer treatment.
When is the H.C. Wainwright Investment Conference?
The conference will take place from September 9 to 11, 2024.
Where will the conference be held?
The event is set to take place at the Lotte New York Palace Hotel.
Who will represent TC BioPharm at the conference?
CEO Bryan Kobel will present the company's business overview.
How can I contact TC BioPharm for inquiries?
Interested parties can reach out via email at ir@tcbiopharm.com.